We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

214 hedge funds and large institutions have $2.44B invested in Mirum Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 85 increasing their positions, 67 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 24

27% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 67

12% more capital invested

Capital invested by funds: $2.19B → $2.44B (+$253M)

4% more funds holding

Funds holding: 205214 (+9)

0.11% more ownership

Funds ownership: 110.36%110.47% (+0.11%)

0% more funds holding in top 10

Funds holding in top 10: 1111 (0)

49% less call options, than puts

Call options by funds: $2.43M | Put options by funds: $4.78M

Holders
214
Holders Change
+9
Holders Change %
+4.39%
% of All Funds
2.87%
Holding in Top 10
11
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.15%
New
34
Increased
85
Reduced
67
Closed
24
Calls
$2.43M
Puts
$4.78M
Net Calls
-$2.35M
Net Calls Change
+$1.12M
Name Holding Trade Value Shares
Change
Change in
Stake
BNP Paribas Financial Markets
26
BNP Paribas Financial Markets
France
$22.5M +$11.2M +237,539 +91%
Millennium Management
27
Millennium Management
New York
$21.6M -$2.25M -47,675 -9%
Goldman Sachs
28
Goldman Sachs
New York
$21.5M -$3.68M -77,985 -14%
Northern Trust
29
Northern Trust
Illinois
$17.5M -$501K -10,623 -3%
CS
30
Candriam SCA
Luxembourg
$17.3M -$2.2M -46,752 -11%
Bank of America
31
Bank of America
North Carolina
$17.1M -$3.02M -64,005 -14%
PCM
32
Penn Capital Management
Pennsylvania
$16.9M +$4.48M +95,092 +34%
Macquarie Group
33
Macquarie Group
Australia
$16.5M +$17.3M +366,751 New
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$16.1M +$8.45M +179,316 +101%
Axa
35
Axa
France
$15.8M -$3.5M -74,274 -17%
Federated Hermes
36
Federated Hermes
Pennsylvania
$15.6M +$16.2M +343,725 +9,440%
Adage Capital Partners
37
Adage Capital Partners
Massachusetts
$15.5M +$9.19M +195,000 +130%
PM
38
Prosight Management
Texas
$15.5M -$5.08M -107,801 -24%
Charles Schwab
39
Charles Schwab
California
$14.8M -$224K -4,761 -1%
Invesco
40
Invesco
Georgia
$14.1M +$667K +14,144 +5%
CSS
41
Cubist Systematic Strategies
Connecticut
$13.4M +$10M +212,918 +254%
JP Morgan Chase
42
JP Morgan Chase
New York
$13M -$4.58M -97,206 -25%
EAM
43
Erste Asset Management
Austria
$11.7M
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$11.7M +$1.51M +32,015 +14%
Raymond James Financial
45
Raymond James Financial
Florida
$11.2M -$344K -7,294 -3%
Bank of New York Mellon
46
Bank of New York Mellon
New York
$11.1M +$5.77M +122,402 +98%
Deutsche Bank
47
Deutsche Bank
Germany
$10.8M +$3.37M +71,421 +42%
UBS Group
48
UBS Group
Switzerland
$10.6M +$2.42M +51,368 +28%
RHJA
49
Rice Hall James & Associates
California
$10.6M -$203K -4,303 -2%
Point72 Asset Management
50
Point72 Asset Management
Connecticut
$10.5M +$10.9M +232,098 New

MIRM Hedge Fund Activity: Q1 2025 in Review

214 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q1 2025, worth a combined $2.44B — up 12% from $2.19B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new MIRM positions and 24 closed out — a net gain of 10 holders — while 85 added to existing stakes and 67 trimmed.

The largest buyer was Polar Capital Holdings, adding an estimated $23.6M. The largest seller was Avidity Partners Management, cutting an estimated $29.5M.

  • 214 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q1 2025, up from 205 in Q4 2024.
  • Funds reported $2.44B of Mirum Pharmaceuticals stock for Q1 2025, up 12% quarter-over-quarter.
  • 34 funds opened new Mirum Pharmaceuticals positions in Q1 2025 and 24 closed out, a net change of +10 holders.
  • The largest Mirum Pharmaceuticals buyer in Q1 2025 was Polar Capital Holdings, an estimated $23.6M added.
  • The largest Mirum Pharmaceuticals seller in Q1 2025 was Avidity Partners Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q1 2025.